European companies, a major source of U.S. medicines, are hopeful that their investments and trade deals with the U.S. will spare them from President Trump’s latest tariff barrage.
Category: Novartis AG
-
What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials
Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information remained secret.
-
U.S. Unveils Price Limits for 10 Costly or Common Medications
The Biden administration said it would have saved $6 billion had the new prices been in effect last year.
-
U.S. to Announce Prices for First Drugs Picked for Medicare Negotiations
The Biden administration said it would have saved $6 billion had the new prices been in effect last year.
-
A Dilemma for Governments: How to Pay for Million-Dollar Therapies
The New York Times – Business:A wave of transformative but hugely expensive treatments is challenging the budgets of health systems in wealthy nations. Now countries with far fewer resources are wrestling with how to cover the therapies.